PapersFlow Research Brief
Advanced Breast Cancer Therapies
Research Guide
What is Advanced Breast Cancer Therapies?
Advanced breast cancer therapies encompass targeted treatments including CDK4/6 inhibitors such as palbociclib combined with letrozole, PARP inhibitors like olaparib for BRCA-mutated cases, and immunotherapies like atezolizumab with nab-paclitaxel, primarily for hormone receptor-positive and triple-negative metastatic breast cancer.
The field includes 32,672 papers on therapies for hormone receptor-positive metastatic breast cancer using CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib, often combined with endocrine agents such as letrozole. Finn et al. (2016) in "Palbociclib and Letrozole in Advanced Breast Cancer" showed that palbociclib plus letrozole extended progression-free survival compared to letrozole alone in ER-positive, HER2-negative advanced breast cancer. Triple-negative breast cancer therapies address subtypes and recurrence patterns, as detailed in studies like Dent et al. (2007) on clinical features.
Topic Hierarchy
Research Sub-Topics
CDK4/6 Inhibitors in Hormone Receptor-Positive Breast Cancer
This sub-topic reviews clinical trials of palbociclib, ribociclib, and abemaciclib combined with endocrine therapy in HR+/HER2- advanced breast cancer. Researchers analyze progression-free survival, overall response rates, and patient selection criteria.
Mechanisms of Resistance to CDK4/6 Inhibitors
This sub-topic elucidates acquired and intrinsic resistance pathways, including RB1 loss, cyclin E amplification, and bypass signaling. Researchers employ single-cell sequencing and CRISPR screens to identify therapeutic vulnerabilities.
Biomarkers for CDK4/6 Inhibitor Response
This sub-topic identifies predictive biomarkers like cyclin D1 expression, PIK3CA mutations, and circulating tumor DNA dynamics. Researchers validate liquid biopsies and multi-omics signatures for personalized therapy.
Combination Therapies with CDK4/6 Inhibitors
This sub-topic explores triplets with PI3K/mTOR inhibitors, immunotherapy, and antibody-drug conjugates beyond ET+CDK4/6 doublets. Researchers assess synergistic efficacy in resistant models and phase II/III trials.
CDK4/6 Inhibitors in Early-Stage Breast Cancer
This sub-topic investigates adjuvant and neoadjuvant CDK4/6 inhibition to prevent recurrence in high-risk HR+ disease. Researchers report pathological complete response rates and invasive disease-free survival from PALLAS, monarchE, and NATALEE trials.
Why It Matters
These therapies improve progression-free survival in metastatic breast cancer patients. In the PALOMA-1 trial, Finn et al. (2016) reported that palbociclib plus letrozole achieved significantly longer progression-free survival than letrozole alone in previously untreated ER-positive, HER2-negative advanced breast cancer, though with higher myelotoxic effects. Robson et al. (2017) in "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation" demonstrated that olaparib monotherapy extended median progression-free survival by 2.8 months and reduced the risk of progression or death by 42% compared to standard therapy in HER2-negative patients with germline BRCA mutations. Schmid et al. (2018) showed that atezolizumab plus nab-paclitaxel prolonged progression-free survival in metastatic triple-negative breast cancer, including PD-L1-positive subgroups. Waks and Winer (2019) in "Breast Cancer Treatment" outline subtype-specific strategies that guide clinical decisions based on estrogen/progesterone receptor expression and ERBB2 amplification.
Reading Guide
Where to Start
"Palbociclib and Letrozole in Advanced Breast Cancer" by Finn et al. (2016) first, as it provides clinical trial evidence of progression-free survival benefits in ER-positive, HER2-negative advanced breast cancer, introducing CDK4/6 inhibition basics.
Key Papers Explained
Finn et al. (2016) in "Palbociclib and Letrozole in Advanced Breast Cancer" established CDK4/6 inhibition with endocrine therapy for hormone receptor-positive cases. Robson et al. (2017) in "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation" extended targeted options to BRCA-mutated HER2-negative metastatic disease with PARP inhibition. Schmid et al. (2018) in "Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer" built on this for triple-negative subtypes via immunotherapy plus chemotherapy. Waks and Winer (2019) in "Breast Cancer Treatment" integrates these into subtype-specific frameworks. Lehmann et al. (2011) in "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies" provides foundational subtyping for therapy selection.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current focus remains on clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and biomarkers for CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer, as per the 32,672 papers in the cluster. No recent preprints or news available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Identification of human triple-negative breast cancer subtypes... | 2011 | Journal of Clinical In... | 5.3K | ✓ |
| 2 | Triple-Negative Breast Cancer: Clinical Features and Patterns ... | 2007 | Clinical Cancer Research | 5.0K | ✓ |
| 3 | Breast Cancer Treatment | 2019 | JAMA | 4.6K | ✕ |
| 4 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Br... | 2018 | New England Journal of... | 4.2K | ✓ |
| 5 | Triple-Negative Breast Cancer | 2010 | New England Journal of... | 4.0K | ✕ |
| 6 | Personalizing the treatment of women with early breast cancer:... | 2013 | Annals of Oncology | 3.6K | ✓ |
| 7 | Olaparib for Metastatic Breast Cancer in Patients with a Germl... | 2017 | New England Journal of... | 3.1K | ✓ |
| 8 | Palbociclib and Letrozole in Advanced Breast Cancer | 2016 | New England Journal of... | 2.8K | ✕ |
| 9 | Breast cancer | 2019 | Nature Reviews Disease... | 2.8K | ✓ |
| 10 | Triple-negative breast cancer molecular subtyping and treatmen... | 2020 | Breast Cancer Research | 2.4K | ✓ |
Frequently Asked Questions
What is the effect of palbociclib and letrozole in advanced breast cancer?
Finn et al. (2016) in "Palbociclib and Letrozole in Advanced Breast Cancer" found that palbociclib combined with letrozole resulted in significantly longer progression-free survival than letrozole alone in previously untreated ER-positive, HER2-negative advanced breast cancer. Myelotoxic effects were higher with the combination. This applies to hormone receptor-positive metastatic cases.
How does olaparib benefit BRCA-mutated metastatic breast cancer patients?
Robson et al. (2017) in "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation" showed olaparib monotherapy provided a median progression-free survival benefit of 2.8 months over standard therapy. The risk of disease progression or death was 42% lower with olaparib. This was observed in HER2-negative patients with germline BRCA mutations.
What are clinical features of triple-negative breast cancer?
Dent et al. (2007) in "Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence" compared 1,601 breast cancer patients and identified distinct clinical features and recurrence patterns for triple-negative cases versus other subtypes. Triple-negative breast cancer lacks estrogen receptor, progesterone receptor, and HER2 expression. Outcomes differ from other breast cancer types.
What survival benefit does atezolizumab plus nab-paclitaxel provide?
Schmid et al. (2018) in "Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer" reported prolonged progression-free survival with atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer, including the intention-to-treat and PD-L1-positive populations. Adverse events matched known profiles of each agent. This was funded by F. Hoffmann-La Roche.
How are breast cancer subtypes treated?
Waks and Winer (2019) in "Breast Cancer Treatment" describe three major subtypes based on estrogen/progesterone receptor expression and ERBB2 amplification, each with distinct risk profiles and strategies. Optimal therapy depends on subtype, stage, and patient factors. Treatment varies accordingly.
Open Research Questions
- ? How can therapeutic resistance to CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer be overcome through combination strategies?
- ? What biomarkers predict response to CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib?
- ? Which molecular subtypes of triple-negative breast cancer respond best to targeted therapies identified in Lehmann et al. (2011)?
- ? What mechanisms underlie cell cycle control disruptions leading to resistance in advanced breast cancer treatments?
- ? How do germline BRCA mutations influence outcomes beyond olaparib in metastatic breast cancer?
Recent Trends
The field encompasses 32,672 works on CDK4/6 inhibitors like palbociclib with letrozole for hormone receptor-positive metastatic breast cancer, covering trials and resistance; growth data over 5 years is not available.
Finn et al. remains highly cited for palbociclib-letrozole benefits.
2016No recent preprints or news in the last 6-12 months reported.
Research Advanced Breast Cancer Therapies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Advanced Breast Cancer Therapies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers